Kiniksa Q3 Revenue Rises to $286 Million; 2026 ARCALYST Outlook Raised

What happened

Kiniksa reported third-quarter 2026 revenue of $286.0 million and net income of $47.3 million, up from $180.9 million and $18.4 million a year earlier. It raised its 2026 ARCALYST net product revenue outlook to $1.045 billion–$1.050 billion from $980 million–$995 million.

Confirmed

Global impact / market context

Higher ARCALYST sales guidance means Kiniksa expects more cash from its main drug, which funds research and development spending without needing outside money. Because the company says its current plan stays cash-flow positive annually, stronger sales reduce the chance it must raise borrowed money or sell new shares.

Analyst inference

Investors compare the raised outlook with the earlier $980 million–$995 million range to judge how much faster ARCALYST sales are growing. Faster growth can support the share price, while the planned Phase 3 KPL-387 and Phase 1 KPL-1161 trials show spending aimed at future revenue beyond ARCALYST.

Analyst inference

What to watch

1. Kiniksa expects research and development expenses of $160 million–$170 million and selling, general and administrative expenses of $270 million–$280 million, and expects its current operating plan to remain cash-flow positive annually. Confirmed
2. Watch whether Kiniksa begins the Phase 1 trial of KPL-1161 by year-end as planned, since a delay would push back a possible future source of revenue and extend spending without near-term sales. Proposed
3. Track how many of the estimated patients receive ARCALYST, since about 23% penetration at quarter end shows room to grow, and higher uptake is the main path to hitting the raised $1.045 billion–$1.050 billion outlook. Analyst inference

Evidence

• Original source link unavailable